Janssen unveils long-term data for HIV drug Symtuza
Janssen has unveiled new late-stage data on Symtuza showing positive long-term efficacy and safety in antiretroviral treatment-naïve adults with HIV.
Read Moreby Selina McKee | Oct 31, 2018 | News | 0
Janssen has unveiled new late-stage data on Symtuza showing positive long-term efficacy and safety in antiretroviral treatment-naïve adults with HIV.
Read Moreby Selina McKee | Jul 18, 2018 | News | 0
Janssen’s Symtuza has been approved US regulators as the first and only complete, darunavir-based single-tablet regimen for the treatment of HIV in adults.
Read Moreby Selina McKee | Oct 9, 2017 | News | 0
Janssen Pharmaceutica’s experimental combination therapy for HIV containing four medicines in a single pill has hit safety and efficacy targets in a late stage trial, results of which have been published in The Lancet HIV.
Read Moreby Selina McKee | Jul 24, 2017 | News | 0
Eleven therapies, including five targeting rare diseases, have taken a giant leap towards being approved in Europe after winning backing from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read Moreby Selina McKee | Sep 13, 2016 | News | 0
Janssen-Cilag has submitted a marketing application to the European Medicines Agency for a new once-daily darunavir-based single tablet regimen (STR) to treat HIV.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
